{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T18:14:35Z","timestamp":1794507275057,"version":"4.9.1"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T00:00:00Z","timestamp":1706140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Objective:<\/jats:bold> This study aimed to investigate the potential association between biological disease-modifying antirheumatic drugs (bDMARDs) and pericarditis and uncover relevant clinical characteristics in ankylosing spondylitis (AS).<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Reports of pericarditis recorded in the FDA Adverse Event Reporting System (FAERS) (January 2004\u2013December 2022) were identified through the preferred term \u201cpericarditis.\u201d Demographic and clinical characteristics were described, and disproportionality signals were assessed through the reporting odds ratio (ROR) and information component (IC). A significant signal was detected if the lower bound of IC (IC<jats:sub>025<\/jats:sub>) was more than zero.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> We found 1,874 reports of pericarditis with bDMARDs (11.3% of cases with fatal outcomes). Adalimumab (IC<jats:sub>025<\/jats:sub> 3.24), infliximab (IC<jats:sub>025<\/jats:sub> 4.90), golimumab (IC<jats:sub>025<\/jats:sub> 5.40), certolizumab (IC<jats:sub>025<\/jats:sub> 5.43), etanercept (IC<jats:sub>025<\/jats:sub> 3.24), secukinumab (IC<jats:sub>025<\/jats:sub> 3.97), and ustekinumab (IC<jats:sub>025<\/jats:sub> 7.61) exhibit significant disproportionality signals compared to other medications in the FAERS database. After excluding pre-existing diseases and co-treated drugs that may increase the susceptibility of pericarditis, the disproportionality signal associated with infliximab, certolizumab, etanercept, secukinumab, and ustekinumab remained strong. Pericarditis cases associated with all bDMARDs were predominantly recorded in women aged 25\u201365 years.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> More reports of pericarditis were detected with AS patients on bDMARDs than with other drugs in the overall database. Further studies are warranted to investigate the underlying mechanisms and identify patient-related susceptibility factors, thus supporting timely diagnosis and safe(r) prescribing of bDMARDs.<\/jats:p>","DOI":"10.3389\/fphar.2024.1275814","type":"journal-article","created":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T04:14:42Z","timestamp":1706156082000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Disproportional signal of pericarditis with biological diseasemodifying antirheumatic drugs (bDMARDs) in patients with ankylosing spondylitis: a disproportionality analysis in the FAERS database"],"prefix":"10.3389","volume":"15","author":[{"given":"Shuang","family":"Xia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Fei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuel","family":"Raschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bi-Kui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Noguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayur","family":"Sarangdhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-An","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,1,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1080\/14712598.2020.1704727","article-title":"Cardiovascular risk in ankylosing spondylitis and the effect of anti-TNF drugs: a narrative review","volume":"20","author":"Atzeni","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"key":"B2","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.therap.2020.02.022","article-title":"Uses of pharmacovigilance databases: an overview","volume":"75","author":"Bihan","year":"2020","journal-title":"Therapie"},{"key":"B4","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3238\/arztebl.2017.0197","article-title":"Cardiovascular comorbidity in inflammatory rheumatological conditions","volume":"114","author":"Braun","year":"2017","journal-title":"Dtsch. Arztebl Int."},{"key":"B5","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/1756-185X.14603","article-title":"Impact of targeted therapies on the risk of cardiovascular events in patients with psoriasis and psoriatic arthritis: a systematic review and aggregate data meta-analysis of randomized controlled trials","volume":"26","author":"Cai","year":"2023","journal-title":"Int. J. Rheum. Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jacc.2019.11.021","article-title":"Management of acute and recurrent pericarditis: JACC state-of-the-art review","volume":"75","author":"Chiabrando","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.semarthrit.2007.08.003","article-title":"Drug-induced lupus due to anti-tumor necrosis factor alpha agents","volume":"37","author":"Costa","year":"2008","journal-title":"Semin. Arthritis Rheum."},{"key":"B8","volume-title":"Pericarditis","author":"Dababneh","year":"2023"},{"key":"B9","doi-asserted-by":"publisher","first-page":"R545","DOI":"10.1186\/ar1715","article-title":"Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey","volume":"7","author":"De Bandt","year":"2005","journal-title":"Arthritis Res. Ther."},{"key":"B10","first-page":"723","article-title":"Treatment of spondyloarthropathy with 5-aminosalicylic acid (mesalazine): an open trial","volume":"27","author":"Dekker-Saeys","year":"2000","journal-title":"J. Rheumatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.therap.2019.01.006","article-title":"Case-non-case studies: principle, methods, bias and interpretation","volume":"74","author":"Faillie","year":"2019","journal-title":"Therapie"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1111\/1756-185X.14414","article-title":"Comparative safety of Janus kinase inhibitors and tumor necrosis factor inhibitors in patients undergoing treatment for rheumatoid arthritis","volume":"25","author":"Fang","year":"2022","journal-title":"Int. J. Rheum. Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1093\/qjmed\/hcx195","article-title":"Cardiac tamponade in systemic lupus erythematosus","volume":"111","author":"Goswami","year":"2018","journal-title":"QJM"},{"key":"B14","doi-asserted-by":"publisher","first-page":"247 e11","DOI":"10.1016\/j.cjca.2013.11.011","article-title":"Drug-induced lupus erythematosus presenting with cardiac tamponade: a case report and literature review","volume":"30","author":"Harnett","year":"2014","journal-title":"Can. J. Cardiol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e17938","DOI":"10.7759\/cureus.17938","article-title":"Cardiovascular risk associated with TNF alpha inhibitor use in patients with rheumatoid arthritis","volume":"13","author":"Hussain","year":"2021","journal-title":"Cureus"},{"key":"B16","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1093\/mrcr\/rxab010","article-title":"A case of eosinophilic granulomatosis with polyangiitis after prolonged intervals of an anti-interleukin-6 receptor antibody for rheumatoid arthritis","volume":"6","author":"Imai","year":"2022","journal-title":"Mod. Rheumatol. Case Rep."},{"key":"B17","doi-asserted-by":"publisher","first-page":"712","DOI":"10.2459\/JCM.0b013e3283340b97","article-title":"Medical therapy of pericardial diseases: part I: idiopathic and infectious pericarditis","volume":"11","author":"Imazio","year":"2010","journal-title":"J. Cardiovasc Med. Hagerst."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1001\/jama.2015.12763","article-title":"Evaluation and treatment of pericarditis: a systematic review","volume":"314","author":"Imazio","year":"2015","journal-title":"JAMA"},{"key":"B19","doi-asserted-by":"publisher","first-page":"3834","DOI":"10.1093\/rheumatology\/keaa876","article-title":"Risk of serious infections in arthritis patients treated with biological drugs: a matched cohort study and development of prediction model","volume":"60","author":"Krabbe","year":"2021","journal-title":"Rheumatol. Oxf."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e34568","DOI":"10.7759\/cureus.34568","article-title":"Adalimumab-induced lupus serositis: a case report and review of the literature","volume":"15","author":"Lee","year":"2023","journal-title":"Cureus"},{"key":"B21","doi-asserted-by":"publisher","first-page":"663088","DOI":"10.3389\/fphar.2021.663088","article-title":"Pericardial toxicities associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database","volume":"12","author":"Ma","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s40264-023-01346-9","article-title":"An exploratory study of the impact of COVID-19 vaccine spontaneous reporting on masking signal detection in EudraVigilance","volume":"46","author":"Micallef","year":"2023","journal-title":"Drug Saf."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1093\/rheumatology\/keu214","article-title":"Is the risk of tumour necrosis factor inhibitor-induced lupus or lupus-like syndrome the same with monoclonal antibodies and soluble receptor? A case\/non-case study in a nationwide pharmacovigilance database","volume":"53","author":"Moulis","year":"2014","journal-title":"Rheumatol. Oxf."},{"key":"B24","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s11095-020-02801-3","article-title":"Comparison of signal detection algorithms based on frequency statistical model for drug-drug interaction using spontaneous reporting systems","volume":"37","author":"Noguchi","year":"2020","journal-title":"Pharm. Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"bbab347","DOI":"10.1093\/bib\/bbab347","article-title":"Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source","volume":"22","author":"Noguchi","year":"2021","journal-title":"Brief. Bioinform"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e36424","DOI":"10.7759\/cureus.36424","article-title":"Infliximab-induced lupus in a patient with psoriatic arthritis who presented with cardiac tamponade: a case report","volume":"15","author":"Obeidat","year":"2023","journal-title":"Cureus"},{"key":"B27","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1136\/annrheumdis-2014-205675","article-title":"Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study","volume":"74","author":"Ogdie","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"104639","DOI":"10.1016\/j.ebiom.2023.104639","article-title":"Cutaneous lupus erythematosus is associated with an increased risk of cardiac and vascular diseases: a large-scale, propensity-matched global retrospective cohort study","volume":"93","author":"Olbrich","year":"2023","journal-title":"EBioMedicine"},{"key":"B29","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1136\/ard-2022-223297","article-title":"Efficacy and safety of non-pharmacological and non-biological interventions: a systematic literature review informing the 2022 update of the ASAS\/EULAR recommendations for the management of axial spondyloarthritis","volume":"82","author":"Ortolan","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"B30","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/s41591-021-01630-0","article-title":"Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection","volume":"28","author":"Patone","year":"2022","journal-title":"Nat. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/ard-2022-223296","article-title":"ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update","volume":"82","author":"Ramiro","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B33","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/apt.16619","article-title":"Worldwide post-marketing safety surveillance experience with tofacitinib in ulcerative colitis","volume":"55","author":"Rubin","year":"2022","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B34","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1111\/1756-185X.13271","article-title":"Gender differences in retention rate of tumor necrosis factor alpha inhibitor treatment in ankylosing spondylitis: a retrospective cohort study in daily practice","volume":"21","author":"Rusman","year":"2018","journal-title":"Int. J. Rheum. Dis."},{"key":"B35","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/nbt.3623","article-title":"Data mining differential clinical outcomes associated with drug regimens using adverse event reporting data","volume":"34","author":"Sarangdhar","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1046\/j.1365-2796.2001.00863.x","article-title":"A case of POEMS syndrome with high concentrations of interleukin-6 in pericardial fluid","volume":"250","author":"Shikama","year":"2001","journal-title":"J. Intern Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","article-title":"Axial spondyloarthritis","volume":"390","author":"Sieper","year":"2017","journal-title":"Lancet"},{"key":"B38","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/acr.23609","article-title":"Subsequent cardiovascular events among patients with rheumatoid arthritis, psoriatic arthritis, or psoriasis: patterns of disease-modifying antirheumatic drug treatment","volume":"71","author":"Sparks","year":"2019","journal-title":"Arthritis Care Res. Hob."},{"key":"B39","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41584-022-00833-0","article-title":"Sexual dimorphism in the prevalence, manifestation and outcomes of axial spondyloarthritis","volume":"18","author":"Stovall","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1056\/NEJMra1406182","article-title":"Ankylosing spondylitis and axial spondyloarthritis","volume":"374","author":"Taurog","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"695","DOI":"10.3390\/healthcare9060695","article-title":"A case of Crohn's disease with cardiac tamponade caused by tuberculous pericarditis: assessment of a rare phenomenon","volume":"9","author":"Tominaga","year":"2021","journal-title":"Healthc. (Basel)"},{"key":"B42","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/s0016-5085(03)00701-7","article-title":"Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study","volume":"125","author":"Vermeire","year":"2003","journal-title":"Gastroenterology"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e630","DOI":"10.1097\/MJT.0000000000001019","article-title":"Adalimumab-associated hemorrhagic pericarditis","volume":"27","author":"Vyas","year":"2020","journal-title":"Am. J. Ther."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1154271","DOI":"10.3389\/fendo.2023.1154271","article-title":"Rheumatoid arthritis increases the risk of heart failure-current evidence from genome-wide association studies","volume":"14","author":"Wang","year":"2023","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1002\/acr.24025","article-title":"2019 update of the American College of rheumatology\/spondylitis association of America\/spondyloarthritis research and treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis","volume":"71","author":"Ward","year":"2019","journal-title":"Arthritis Care Res."},{"key":"B46","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1136\/ard-2022-223298","article-title":"Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis","volume":"82","author":"Webers","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"B47","doi-asserted-by":"publisher","first-page":"3907","DOI":"10.1007\/s10238-023-01055-8","article-title":"Effect of age on the risk of immune-related adverse events in patients receiving immune checkpoint inhibitors","volume":"23","author":"Yang","year":"2023","journal-title":"Clin. Exp. Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"107049","DOI":"10.1016\/j.intimp.2020.107049","article-title":"Tumor necrosis factor inhibitor-induced pleuropericarditis: a retrospective evaluation using data from VigiBase","volume":"89","author":"Zhang","year":"2020","journal-title":"Int. Immunopharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1275814\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T04:14:47Z","timestamp":1706156087000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1275814\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,25]]},"references-count":48,"alternative-id":["10.3389\/fphar.2024.1275814"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1275814","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.3389\/fphar.2024.1275814.s001","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.3389\/fphar.2024.1275814.s002","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.3389\/fphar.2024.1275814.s003","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.3389\/fphar.2024.1275814.s004","asserted-by":"subject"}]},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,25]]},"article-number":"1275814"}}